echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Summary of studies on immunotherapy combined with platinum and etoposide regimens in the first-line treatment of extensive-stage small cell lung cancer ELCC 2022

    Summary of studies on immunotherapy combined with platinum and etoposide regimens in the first-line treatment of extensive-stage small cell lung cancer ELCC 2022

    • Last Update: 2022-04-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The 2022 European Lung Cancer Conference (ELCC) will be held from March 30 to April 2 local time, and a number of studies led by Chinese experts have been selected for this event
    .

    Small cell lung cancer (SCLC) is a less common pathological subtype of lung cancer, and its prognosis is generally poor
    .

    Currently, the recommended treatment for extensive-stage small cell lung cancer (ES-SCLC) in NCCN guidelines is platinum combined with etoposide (EP)
    .

    In recent years, with the popularity of immunotherapy, researches exploring the application of immunotherapy in SCLC have received more and more attention, such as the CASPIAN study and the CANTABRICO study
    .

    In this meeting, the CANTABRICO study announced the safety and efficacy analysis results of immunotherapy combined with EP regimen, and the CASPIAN study announced the clinical and molecular characteristics of long-term survivors
    .

    CANTABRICO study published the first-line treatment results of durvalumab combined with EP regimen Research Background Most SCLC patients have developed to extensive stage at the time of diagnosis, and ES-SCLC patients usually have a poor prognosis
    .

    The previous CASPIAN trial showed that durvalumab combined with EP regimen as first-line treatment significantly improved overall survival (OS) in ES-SCLC patients compared with control patients
    .

    This study (CANTABRICO, NCT04712903) will evaluate the safety and efficacy of durvalumab combined with platinum + etoposide (EP) in ES-SCLC populations in the real world
    .

    Methods This is a phase IIIb, single-arm, multicenter study of 101 patients with ES-SCLC aged ≥18 years, treatment-naïve, ECOG PS 0-2, and at least one measurable lesion
    .

    All patients received 4-6 cycles of durvalumab combined with EP first-line therapy (durvalumab 1500 mg, d1; cisplatin or carboplatin, d1; etoposide, d1-3; q3w), Thereafter, durvalumab was administered every 4 weeks until disease progression (PD) or intolerable toxicity
    .

    The primary endpoint of the study is safety, and secondary endpoints include objective response rate (ORR), etc.
    The detailed design is shown in Figure 1
    .

    Figure 1 Study Design Study Results Patient Baseline and Treatment Status The median patient age was 65 years, 67% of patients were male, 94% of patients had ECOG 0-1, 33% of patients had liver metastases, and 11% had brain metastases transfer
    .

    At data cutoff on February 28, 2022, 22 patients were still receiving durvalumab
    .

    84% of patients completed ≥4 cycles of chemotherapy, 40% completed ≥5 cycles of chemotherapy, 33% completed 6 cycles of chemotherapy, and the median number of cycles of durvalumab was 8
    .

    The ORR of patients with clinical benefit was 52%, 4 patients achieved complete remission, 48 patients achieved partial response, and 33 patients had stable disease, with a clinical benefit rate of 84%
    .

    The researchers compared the disease remission in this study with that of CASPAIN.
    The clinical benefit rates of the two studies were similar, and other comparisons are shown in Table 1
    .

    Table 1 Disease remission of patients and safety analysis compared with CASPAIN study There were 63 cases of grade 3-4 adverse events and 7 cases of grade 5 adverse events in all patients; 21 cases of immune-related adverse events occurred in all patients, of which 6 cases were 3 - Grade 5 immune-related adverse events
    .

    Etoposide treatment was discontinued due to adverse events in 10 patients, platinum therapy was discontinued due to adverse events in 2 patients, durvalumab treatment was delayed due to adverse events in 89 patients, and duvalumab was discontinued due to adverse events in 8 patients.
    4 patients died in limumab treatment
    .

    CONCLUSIONS This study showed that increasing the number of cycles of EP chemotherapy had no adverse effect, as more than 40% of patients tolerated more than 4 cycles of chemotherapy and 32% tolerated 6 cycles of chemotherapy
    .

    Only 1 patient discontinued chemotherapy due to toxicity after cycle 5, and the most common adverse event leading to chemotherapy dose adjustment was chemotherapy-induced hematologic toxicity
    .

    The clinical benefit profile of this study was similar to that of the CASPAIN trial
    .

    Clinical and Molecular Characteristics of Long-Term Surviving Patients in the CASPIAN Study Background The Phase III study of the CASPIAN trial showed that first-line durvalumab combined with EP chemotherapy significantly improved OS compared with EP chemotherapy, with a median follow-up > 3 This benefit persisted after one year (HR 0.
    71; 95% CI 0.
    60-0.
    86, nominal p=0.
    0003)
    .

    Here, the investigators present the clinical and molecular characteristics of long-term survivors in the CASPIAN trial
    .

    Research methods 805 ES-SCLC patients were randomized to receive durvalumab + EP, durvalumab + Tremelimumab + EP or EP in a 1:1:1 ratio
    .

    The investigators assessed the clinical characteristics of patients with long-term survival (LTS; n = 94) in a post hoc analysis, defined as those after data cutoff on March 22, 2021 (median follow-up, 39.
    4 months) patients who are still alive
    .

    With OS ≥18 months as the cutoff, we assessed PD-L1 expression and tissue tumor mutational burden (tTMB) in biomarker-evaluable populations (BEPs)
    .

    RESULTS: There were 44 (16%), 37 (14%), and 13 (5%) LTS patients in the durvalumab+EP, durvalumab+Tremelimumab+EP, and EP groups, respectively
    .

    In terms of baseline characteristics, LTS patients had a lower incidence of brain/liver metastases compared with all treated patients (ITT) (Table 2)
    .

    Compared with ITT patients, the median treatment dose of immunotherapy + EP regimen was higher in LTS patients, and the proportion of patients who received ≥4 cycles of EP chemotherapy was also higher
    .

    At the time of data cutoff, 46 LTS patients were still receiving durvalumab
    .

    In the durvalumab + EP treatment group, ORR was 89% for LTS patients and 79% for ITT patients; 24-month PFS was as high as 65% for LTS patients and 11% for ITT patients
    .

    In the durvalumab + tremelimumab + EP treatment group, ORR was 92% for LTS patients and 74% for ITT patients; 24-month PFS was as high as 67% for LTS patients and 12% for ITT patients
    .

    The incidence of serious adverse events in LTS patients was similar to that in ITT patients (Table 2)
    .

    Only in the durvalumab + Tremelimumab + EP group, the proportion of patients with PD-L1 ≥ 1% in the LTS population with OS ≥ 18 months was higher than that in the ITT population with OS < 18 months, and there was no significant difference in the other two groups.
    differences (Table 2)
    .

    Table 2 Patient baseline and outcome table Study conclusions The number of LTS patients in the durvalumab + EP group was more than 3 times that of the EP group
    .

    Although some LTS patients had brain/liver metastases at baseline, LTS patients were more likely to have favorable prognostic characteristics compared with ITT patients
    .

    Notably, the majority of LTS patients completed EP treatment compared with ITT patients, and in the immunotherapy + EP group, LTS patients had significantly higher overall treatment doses, and these patients also achieved higher ORRs and longer durations.
    PFS
    .

    No cumulative toxicity based on serious adverse events was found
    .

    Reference 1.
    D.
    Isla, E.
    Arriola, MR Garcia Campelo, et al.
    Phase IIIb study of durvalumab plus platinumeetoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Treatment patterns of chemotherapy combination phase with durvalumab.
    ELCC 2022 142P.
    2.
    N.
    Reinmuth, JW Goldman, MC Garassino, et al.
    Durvalumab (D) ± tremelimumab (T) + platinum-etoposide(EP) in 1L extensive-stage (ES) SCLC: Characteristics of longterm survivors in the CASPIAN study.
    ELCC 2022 141O.
    Editor: Youshi Reviewer: Youshi Typesetting: XY Execution: XY
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.